News |

I presented our work on HbF induction by BMS-986470 at EHA 2026 in Stockholm, Sweden.

Thu, 11 Jun 2026 00:00:00 +0000

Excited to share that I presented our work on HbF induction by BMS-986470, a novel CELMoD agent for sickle cell disease, at the European Hematology Association (EHA) Annual Congress 2026 in Stockholm, Sweden.

Read the full story .

Our multi-omics study revealing an RNA-seq Ikaros/Aiolos signature for CELMoD response in multiple myeloma is accepted at AACR 2026!

Wed, 08 Apr 2026 00:00:00 +0000

Excited to share that our abstract on a novel Ikaros/Aiolos transcriptional signature in multiple myeloma has been accepted and will be presented at the AACR Annual Meeting 2026 (April 17–22, San Diego, CA)!

Our work presents an RNA-seq based Ik/Ai activity score derived from preclinical genomic data and validates its association with patient response in CELMoD-treated multiple myeloma patients.

Read the full story .

We are excited to announce ContextMap!

Sat, 21 Feb 2026 00:00:00 +0000

We are excited to announce ContextMap to provide session intelligence and auto-summarize the project’s evolution across your Claude Code sessions.

ContextMap automatically tracks your workflow, maps out critical decisions, and generates beautiful self-contained HTML reports so you never lose your train of thought again.

Catch me at NeurIPS 2025!

Wed, 03 Dec 2025 00:00:00 +0000

I’ll be attending NeurIPS 2025! Looking forward to connecting with the community and discussing how AI is transforming drug discovery and genomics research!

Our paper on Golcadomide is published in Blood Cancer Discovery

Wed, 05 Nov 2025 00:00:00 +0000

Excited to share that our work on Golcadomide, an oral CELMoD agent targeting IKZF1/3 for Diffuse Large B-Cell Lymphoma, has been published in Blood Cancer Discovery!

This study demonstrates how molecular glue degraders can selectively eliminate cancer cells by hijacking the ubiquitin-proteasome system.